Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma

An, Yang; Gao, Song; Zhao, Wenchao; Qiu, Bao‐An; Xia, Nian-Xin; Zhang, Pengjun; Fan, Ziwen

doi:10.3748/wjg.v24.i24.2596

Cited by 31 publications

(23 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seventeen studies were further excluded after full-text review, because they were animal studies (n = 1), not designed as diagnostic studies (n = 5), reported exosomal miR-122 expression rather than circulating miR-122 expression (n = 3), evaluated single nucleotide polymorphisms of miR-122 (n = 1), or reported diagnostic efficacies with no available data for miR-122 (n = 7). Finally, 13 studies were included [11][12][13][14][16][17][18][19][20][21][22][23][24].…”

Section: Studies Identified By Databasementioning

confidence: 99%

“…Subsequently, we evaluated whether the diagnostic performance of serum miR-122 differed for discrimination of HCC from the different control conditions. Pooled results from six studies [11,12,18,19,21,23] that evaluated the diagnostic performance of serum miR-122 for HCC versus the healthy control condition showed a summary sensitivity of 0.85 (95% CI: 0.77-0.90) and specificity of 0.83 (95% CI: 0.74-0.89; Figure 2(b)). The summary AUC was 0.91 (95% CI: 0.88-0.93), according to the synthesized ROC curve (Figure 3(b)).…”

Section: Meta-analysis Of the Value Of Circulating Mir-122 For Hcc DImentioning

confidence: 99%

“…However, due to the small number of studies included, they were unable to evaluate the efficacy of circulating miR-122 for discriminating HCC patients from various control patient populations [15]. Since the publication of their meta-analysis, several additional studies regarding the diagnostic efficacy of miR-122 for HCC have been published [16][17][18][19][20][21][22][23][24]. Therefore, we aimed to quantitatively evaluate the potential diagnostic performance of circulating miR-122 for HCC in an updated meta-analysis.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis

Zhao

Lin

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Circulating microRNA-122 (miR-122) has been recognized as a marker of hepatocellular carcinoma (HCC). The current meta-analysis was performed to quantitatively evaluate the diagnostic performance of circulating miR-122 for HCC. Methods. Related studies that evaluated the diagnostic performance of circulating miR-122 determined from pathophysiological examination for HCC were obtained by systematic searches of the PubMed and Embase databases. A randomized fixed effects model was applied according to the heterogeneity among studies. The pooled sensitivity, specificity, and area under the summary receiver operating characteristic curve (AUC) were calculated to evaluate the diagnostic accuracy. Publication bias was detected by Deeks' funnel plot asymmetry test. Results. Thirteen studies providing data for 920 HCC patients and 1217 controls were included in the meta-analysis. The pooled sensitivities, specificities, and AUCs of serum miR-122 were 0.76, 0.75, and 0.82, respectively, for discriminating HCC patients from overall controls; 0.85, 0.83, and 0.91, respectively, for discriminating HCC patients from healthy controls; 0.79, 0.82, and 0.87, respectively, for discriminating HCC from HBV or HCV infection; and 0.65, 0.75, and 0.74, respectively, for discriminating HCC from liver cirrhosis or dysplastic nodule formation. No significant publication bias was detected. Conclusions. Serum miR-122 confers moderate efficacy for discriminating HCC patients from healthy controls or patients with HBV or HCV infection, but not for discriminating HCC patients from those with liver cirrhosis or dysplastic nodule formation.

show abstract

Section: Studies Identified By Databasementioning

confidence: 99%

Section: Meta-analysis Of the Value Of Circulating Mir-122 For Hcc DImentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis

Zhao

Lin

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…In addition, in NASH it has . Finally, in NAFLD-related HCC the up-regulation of miR-10a, miR-33a, miR-144, miR-155, miR-183, miR-375 and miR-423 and the down-regulation of miR-229 and miR-7706 were found [65][66][67] .…”

Section: Pathogenesismentioning

confidence: 99%

Fat and hepatocellular carcinoma

Balsano¹,

Porcu²,

Sideri³

et al. 2018

View full text Add to dashboard Cite

Obesity and diabetes are associated with the onset of hepatocellular carcinoma (HCC). These two illnesses correlate also with the development of non-alcoholic fatty liver disease (NAFLD). Currently, NAFL is considered the leading form of chronic liver disease in the Western industrialized countries. Insulin resistance is the common pathogenic factor among these three pathologies. NAFL is characterized by fat accumulation in the liver that involves greater than 5% of the liver parenchyma with no evidence of hepatocyte injury. However, NAFL may progress toward non-alcoholic steatohepatitis that in turn may lead to advanced fibrosis, cirrhosis and HCC. It is alarming that NAFLD related HCC has been, at present, considered as a growing burden worldwide, and its prevalence is tending to further increase together with the increasing incidence of obesity and diabetes. Worthy of note is that in the presence of chronic accumulation of fat in the liver it has been reported the emergence of HCC during chronic liver disease in absence of liver cirrhosis, usually the major risk factor for the development of HCC. Thus, in the future NAFLD related HCCs will place a growing strain on health-care systems from the need for their management. Unfortunately, most of the NAFLD related HCC patients are diagnosed at advanced stages and are characterized by a poor prognosis, because they are ineligible to radical treatments. Thus, it is urgent to boost up new screening policies to make early diagnoses, as well as to develop preventive-therapeutic strategies.

show abstract

“…Increased expression of serum miRNA-10a-5p has been described in a CHB cohort with substantial histological features 388 as well as a study of patients with HCC. 389 The latter study also described increased circulating miRNA-10a-5p levels in patients with chronic hepatitis compared with healthy control patients, however limited patient characteristics were provided. 389 Increased tissue expression of miRNA-10a-5p has also been reported in HCV-associated dysplastic nodules and HCV-associated HCC compared with non-tumorous surrounding tissue, 315 whereas another study reported decreased tissue miRNA-10a-5p expression in HCC of mixed aetiologies.…”

Section: Mirna-10a-5p and Mirna-10b-5pmentioning

confidence: 93%

Investigating the potential of circulating microRNAs as non-invasive biomarkers in cirrhosis and hepatocellular carcinoma

Weis¹

View full text Add to dashboard Cite

Identification of 5 miRNA candidates (miRNA-10a-5p, miRNA-10b-5p, miRNA101-3p, miRNA 22-3p and miRNA-27b-3p) in the serum of 136 patients with cirrhosis that are differentially expressed according to disease severity in compensated cirrhosis (n=30), cirrhosis with varices (n=30), cirrhosis with ascites ± varices (n=60), and cirrhosis with variceal bleeding (n=16). MiRNA panels were assembled to distinguish patients with specific complications with the following diagnostic performance: • Varices panel (miRNA-10b-5p + miRNA-101-3p) with an AUC of 0.78 (95% CI 0.66-0.90, p<0.001) • Ascites panel (miRNA-10a-5p + miRNA-146a-5p) with an AUC of 0.83 (95% CI 0.75-0.92, p<0.001) • Variceal bleeding panel (miRNA-10a-5p) with an AUC of 0.80 (95% CI 0.65-0.95, p<0.001) • Decompensation panel, grouping ascites and variceal bleeding patients (miRNA-10a-5p, miRNA-146a-5p + miRNA-423-3p) with an AUC of 0.78 (95% CI 0.70-0.86, p<0.001). Combining platelet count < 150 (x10 9 /L) 2 with the miRNA panels improved the performance of the Varices panel and the Ascites panel (with AUCs of 0.84 and AUC of 0.87, respectively). This thesis has identified several differentially-expressed miRNA candidates across a clinically relevant spectrum of CLD and assembled promising panels of miRNAs that warrant further investigation for their diagnostic potential. Preliminary efforts to explore the possible functional roles of 2 candidates in HCC were unrewarding but further studies can build on these findings by optimising experimental conditions, validating identified miRNA candidates, and testing the prognostic potential of validated miRNAs as clinically-useful non-invasive biomarkers.

show abstract

Novel serum microRNAs panel on the diagnostic and prognostic implications of hepatocellular carcinoma

Cited by 31 publications

References 36 publications

Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis

Circulating MicroRNA-122 for the Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis

Fat and hepatocellular carcinoma

Investigating the potential of circulating microRNAs as non-invasive biomarkers in cirrhosis and hepatocellular carcinoma

Contact Info

Product

Resources

About